---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-084428"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2025-04-17T23:59:59+00:00"
generated_at: "2026-05-23T12:26:45.733164+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam Pharma appoints Adele Gulfo as independent director

## Summary
- Adele Gulfo, former CEO of Sumitomo Pharma America's Biopharma Unit, joins Board effective April 15, 2025.
- Granted options for 50,700 ordinary shares at $16.06/share, vesting over 3 years with 33% on first anniversary.
- Granted 10,860 RSUs vesting in equal thirds over three years from April 15, 2025.
- Gulfo led launches of Lipitor and Crestor; oversaw $12B+ revenue at Pfizer's U.S. primary care unit.
- Appointment adds commercial expertise as company prepares for potential obicetrapib launch in 2026.

## SEC filing metadata
- accession: 0001193125-25-084428
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2025-04-17T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312525084428/0001193125-25-084428-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312525084428/d924591d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-084428
- JSON: https://secwatch.observer/filing/0001193125-25-084428.json
- Plain text: https://secwatch.observer/filing/0001193125-25-084428.txt

## Key facts
- Executive change
  Adele Gulfo was appointed as Director at NewAmsterdam Pharma Co N.V..
  - Action: appointed
  - Role: Director
  source text: On April 15, 2025, the board of directors (the “Board”) of NewAmsterdam Pharma Company N.V. (the “Company”) appointed Adele Gulfo to serve as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1936258/000119312525084428/0001193125-25-084428-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.